The PD1/PDL1 axis, a promising therapeutic target in aggressive breast cancers. (3rd March 2016)

• Record Type: Journal Article
• Authors: Bertucci, François; Finetti, Pascal; Birnbaum, Daniel; Mamessier, Emilie
• Is Part Of: Oncoimmunology. Volume 5:Number 3(2016)
• Publication Date: 2016-03-03
• Subjects: Breast cancer -- chemotherapy -- immune response -- inflammatory breast cancer -- PDL1 -- survival -- triple-negative; Tumors -- Immunological aspects -- Periodicals; Neoplasms -- therapy -- Periodicals; Immunotherapy -- Periodicals; 616.994
• DOI: 10.1080/2162402X.2015.1085148
• Languages: English
• ISSNs: 2162-402X

Abstract

ABSTRACT: Analysis of PDL1 mRNA expression in ∼5, 500 breast cancers showed PDL1 upregulation in 38% of basal tumors and 38% of inflammatory breast cancers (IBC). Upregulation, associated with signs of strong cytotoxic local immune response, was associated with a better survival in the basal or triple-negative subtypes, and with a better pathological response to chemotherapy in these subtypes and IBC. Reactivation of dormant tumor-infiltrating lymphocytes (TILs) by PD1/PDL1-inhibitors represents a promising strategy in these aggressive tumors.